Droxidopa / Pyridostigmine in Orthostatic Hypotension

• Status: Completed
• Trial end date: 2021-01-19
• Target enrollment: 0
• Participant gender: All

Summary

The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE). This combination should result in enhanced orthostatic release of NE. The investigators have already demonstrated that pyridostigmine does not raise supine blood pressure.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)
• Treatments: Bromides; Droxidopa; Pyridostigmine Bromide

Criteria

1. The presence of orthostatic hypotension (fall in systolic BP greater than or equal to 30 mm Hg) is required for this study;

2. Autonomic testing and clinical evaluation demonstrates OH to be of neurogenic etiology.